INCY vs. CRL, MEDP, EXEL, NRC, ICLR, IQV, EXAS, PODD, DVA, and RDY
Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Charles River Laboratories International (CRL), Medpace (MEDP), Exelixis (EXEL), National Research (NRC), ICON Public (ICLR), IQVIA (IQV), Exact Sciences (EXAS), Insulet (PODD), DaVita (DVA), and Dr. Reddy's Laboratories (RDY).
Incyte (NASDAQ:INCY) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Incyte has higher earnings, but lower revenue than Charles River Laboratories International. Incyte is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
Incyte received 727 more outperform votes than Charles River Laboratories International when rated by MarketBeat users. Likewise, 73.63% of users gave Incyte an outperform vote while only 61.57% of users gave Charles River Laboratories International an outperform vote.
Incyte has a net margin of 16.17% compared to Charles River Laboratories International's net margin of 11.49%. Charles River Laboratories International's return on equity of 16.53% beat Incyte's return on equity.
97.0% of Incyte shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 17.5% of Incyte shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Incyte presently has a consensus target price of $75.50, suggesting a potential upside of 43.65%. Charles River Laboratories International has a consensus target price of $253.23, suggesting a potential upside of 9.10%. Given Incyte's higher probable upside, equities research analysts plainly believe Incyte is more favorable than Charles River Laboratories International.
In the previous week, Incyte had 20 more articles in the media than Charles River Laboratories International. MarketBeat recorded 29 mentions for Incyte and 9 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.64 beat Incyte's score of 0.32 indicating that Charles River Laboratories International is being referred to more favorably in the news media.
Incyte has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Summary
Incyte beats Charles River Laboratories International on 9 of the 17 factors compared between the two stocks.
Get Incyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
